SteadyMed ^{Priced, Nasdaq: STDY}

Our primary focus is to obtain approval for the sale of Trevyent for the treatment of pulmonary arterial hypertension, or PAH. We are also developing two product candidates for the treatment of post-surgical and acute pain in the home setting. Our product candidates are enabled by our proprietary PatchPump, which is a discreet, water-resistant and disposable drug administration technology that is aseptically pre-filled with liquid drug at the site of manufacture and pre-programmed to deliver an accurate, steady flow of drug to a patient, either subcutaneously or intravenously. Our lead product candidate, Trevyent, is being developed for the treatment of PAH, a progressive orphan disease that may eventually lead to heart failure and premature death. Approximately 30,000 patients in the United States are currently diagnosed with PAH. Trevyent is designed to provide an effective alternative for PAH patients that overcomes the limitations associated with the administration of the current market-leading prostacyclin PAH therapy, Remodulin (treprostinil sodium), which is produced by United Therapeutics Corporation. The annual cost of Remodulin is reported to be between approximately $125,000 and $175,000 per patient and United Therapeutics generated Remodulin revenues of $553.7 million in 2014 and $491.2 million in 2013.